New hope for kids with Crohn's: drug combo trial launches
NCT ID NCT05043870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for children aged 6-18 with Crohn's disease: one group gets infliximab alone, another gets immunosuppressives alone, and a third gets both. The goal is to see which approach leads to more kids achieving remission (feeling better and showing healed intestines) after 54 weeks. The trial is currently recruiting 128 participants in China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN, ONLY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201102, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Turning play into therapy: Ride-On toys may boost arm strength in kids with hemiplegia
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?